Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06032026 · ClinicalTrials.gov registry record · Early Phase 1

Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15

A Early Phase 1 study of Tauopathies, sponsored by University of Pennsylvania.

Recruiting
Registry status
Early Phase 1
Development phase
70
Enrollment target
1
Study location

NCT06032026: Recruiting Early Phase 1 study of Tauopathies, sponsored by University of Pennsylvania.

NCT06032026 is a Early Phase 1 study of Tauopathies that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 70 participants, roughly in line with the 70-participant average among 5 other Tauopathies trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06032026, a Early Phase 1 study of Tauopathies, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
Early Phase 1
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C HY-2-15. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with Multiple System Atrophy (MSA). The investigators will compare uptake in people with MSA with people with Parkinson disease (PD) and progressive supranuclear palsy (PSP) as well as healthy volunteers. This multicenter project funded by an NIH U19 grant, is centered at U Pennsylvania (Penn, Grant PI: Robert Mach) in collaboration with U Pittsburgh (Pitt) (not a clinical site), Yale U, U of California at San Francisco (UCSF) and Washington University in St. Louis (WU). The University of Pennsylvania will act as the sIRB for this multi-center human subjects project and participants will be recruited from all sites.

Primary Outcome

Determine biodistribution of the radioactive investigational drug, 11C HY-2-15

Conditions Studied

Tauopathies

Interventions

  • DRUG 11C-HY-2-15 PET
  • DIAGNOSTIC_TEST brain MRI
  • DIAGNOSTIC_TEST Amyloid PET scan
  • BEHAVIORAL Neurological assessments

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2023-07-20
Est. Completion 2028-07-31
Phase Early Phase 1
University of Pennsylvania

1,423 total trials

What NCT06032026 shows while recruiting

NCT06032026 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, roughly in line with the 70-participant average among 5 other Tauopathies trials with a reported enrollment target.

The record links to 1 condition, with Tauopathies appearing as the primary indexed condition, and to 4 interventions - of which 11C-HY-2-15 PET is the first listed.

NCT06032026 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06032026 about?

NCT06032026 is a clinical study titled "Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15". The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C HY-2-15. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with Multiple System Atrophy (MSA). The investigators will compare uptake i...

What is the current status of trial NCT06032026?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 70 participants. The study started on 2023-07-20. Estimated completion is 2028-07-31.

What conditions does trial NCT06032026 study?

This clinical trial studies the following conditions: Tauopathies.

What interventions are being tested in trial NCT06032026?

The interventions under investigation include: 11C-HY-2-15 PET (DRUG), brain MRI (DIAGNOSTIC_TEST), Amyloid PET scan (DIAGNOSTIC_TEST), Neurological assessments (BEHAVIORAL).

Who is sponsoring clinical trial NCT06032026?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06032026 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Tauopathies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06032026

Source: ClinicalTrials.gov NCT06032026, the US trial registry maintained by the National Library of Medicine. NCT06032026 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.